Cytokinetics (CYTK) Stock Price, Quote, News & History

Comments

Cytokinetics Inc (CYTK) Stock Price, Quote, News & History

CYTKNASDAQ

Trade with Public

$62.42

2.013.33%

At close: Mar 9, 5:00 PM EST

$60.87

-1.55-2.49%

After Hours: 6:32 PM EST

OverviewNews Earnings Options Guidance Analyst Ratings Insider Trades Short Interest Government Trades Stock Report

Key Statistics

Open

$60.35

Close

$62.42

Volume / Avg.

2.56M / 1.92M

Day Range

$59.91 - $62.72

52 Wk Range

29.31 - 70.98

Market Cap

$7.44B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

42

Short Interest

15.66%

Days to Cover

8.57

Recent Cytokinetics Inc News

The Year-End 2025 Biotech Rally And What It Means For 2026

Hillary Remy

Why Is Edgewise Therapeutics Stock Soaring Wednesday?

Edgewise's EDG-7500 showed clinical activity and a favorable safety profile in Phase 2 trial for hypertrophic cardiomyopathy.

Vandana Singh

Cytokinetics Wins FDA Nod For Heart Drug Myqorzo

FDA approved CYTK's Myqorzo for oHCM. It reduces heart's pumping ability, has a warning for heart failure and expected to launch in 2026.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-510.01M

Investing Cash Flow (TTM)

16.67M

Financing Cash Flow (TTM)

524.46M

Free Cash Flow (TTM)

-534.82M

Capital Expenditure (TTM)

-24.81M

Net Change in Cash (TTM)

31.12M

Analyst Trends and Forecast

2

Nov 25

7

Dec 25

4

Jan

4

Feb

1

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$7.79B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

82.40

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-10.83%

Earnings Yield % (FWD)

-10.55%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$5.40

Company Debt

Total Debt

$1.16B

LT Debt

$1.12B

LT Debt Issuance (TTM)

$729.46M

LT Debt Repayment (TTM)

-$413.51M

Total Cash

$122.52M

Debt to Equity

-

Issuance of Debt (TTM)

$315.95M

Repayment of Debt (TTM)

-$413.51M

Key Statistics

Open

$60.35

Close

$62.42

Volume / Avg.

2.56M / 1.92M

Day Range

$59.91 - $62.72

52 Wk Range

29.31 - 70.98

Market Cap

$7.44B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

42

Short Interest

15.66%

Days to Cover

8.57

About

Sector

Health Care

Industry

Biotechnology

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle ...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Cytokinetics (CYTK) stock?

A

You can purchase shares of Cytokinetics (NASDAQ:CYTK) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Cytokinetics (CYTK) competitors?

A

Other companies in Cytokinetics’s space includes: Immunovant Inc (NASDAQ:IMVT), Cogent Biosciences Inc (NASDAQ:COGT), Celcuity Inc (NASDAQ:CELC), PTC Therapeutics Inc (NASDAQ:PTCT) and Vaxcyte Inc (NASDAQ:PCVX).

Q

What is the forecast, or price target, for Cytokinetics (CYTK) stock?

A

Cytokinetics has a consensus price target of $86.23.

Q

What is the current price for Cytokinetics (CYTK)?

A

The stock price for Cytokinetics (NASDAQ: CYTK) is $60.8662 last updated March 9, 2026 at 6:32 PM EDT.

Q

Does Cytokinetics (CYTK) pay a dividend?

A

There are no upcoming dividends for Cytokinetics.

Q

When is Cytokinetics (NASDAQ:CYTK) reporting earnings?

A

Cytokinetics does not have any upcoming earnings scheduled.

Q

Is Cytokinetics (CYTK) going to split?

A

There is no upcoming split for Cytokinetics.

Q

What sector and industry does Cytokinetics (CYTK) operate in?

A

Cytokinetics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Cogent Biosciences Inc

Protagonist Therapeutics Inc

NASDAQ:PTGX

$96.30

-0.37%

Arrowhead Pharmaceuticals Inc

NASDAQ:ARWR

$60.67

%

CRISPR Therapeutics AG

NASDAQ:CRSP

$58.51

-0.46%

Key Statistics

Open

$60.35

Close

$62.42

Volume / Avg.

2.56M / 1.92M

Day Range

$59.91 - $62.72

52 Wk Range

29.31 - 70.98

Market Cap

$7.44B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

42

Short Interest

15.66%

Days to Cover

8.57

Recent Cytokinetics Inc News

The Year-End 2025 Biotech Rally And What It Means For 2026

Hillary Remy

Why Is Edgewise Therapeutics Stock Soaring Wednesday?

Edgewise's EDG-7500 showed clinical activity and a favorable safety profile in Phase 2 trial for hypertrophic cardiomyopathy.

Vandana Singh

Cytokinetics Wins FDA Nod For Heart Drug Myqorzo

FDA approved CYTK's Myqorzo for oHCM. It reduces heart's pumping ability, has a warning for heart failure and expected to launch in 2026.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-510.01M

Investing Cash Flow (TTM)

16.67M

Financing Cash Flow (TTM)

524.46M

Free Cash Flow (TTM)

-534.82M

Capital Expenditure (TTM)

-24.81M

Net Change in Cash (TTM)

31.12M

Analyst Trends and Forecast

2

Nov 25

7

Dec 25

4

Jan

4

Feb

1

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$7.79B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

82.40

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-10.83%

Earnings Yield % (FWD)

-10.55%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$5.40

Company Debt

Total Debt

$1.16B

LT Debt

$1.12B

LT Debt Issuance (TTM)

$729.46M

LT Debt Repayment (TTM)

-$413.51M

Total Cash

$122.52M

Debt to Equity

-

Issuance of Debt (TTM)

$315.95M

Repayment of Debt (TTM)

-$413.51M

Key Statistics

Open

$60.35

Close

$62.42

Volume / Avg.

2.56M / 1.92M

Day Range

$59.91 - $62.72

52 Wk Range

29.31 - 70.98

Market Cap

$7.44B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

42

Short Interest

15.66%

Days to Cover

8.57

About

Sector

Health Care

Industry

Biotechnology

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle ...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry